JBI-589 free base · Synonyms: JBI 589 · JBI589

JBI-589 is a non-covalent PAD4 isoform-selective inhibitor.

For research use only. Not for human or veterinary use.

Target Protein Arginine Deiminase

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

JBI-589 structure

CAS No.: 2308504-22-3

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
25 mg	USD 798.00	BP-02375-25mg	In stock	Get quote
50 mg	USD 1,380.00	BP-02375-50mg	In stock	Get quote
100 mg	USD 2,180.00	BP-02375-100mg	In stock	Get quote
250 mg	Inquire	BP-02375-250mg	In stock	Inquire

Custom Size Bulk Inquiry

Description

JBI-589 is a non-covalent PAD4 isoform-selective inhibitor. JBI-589 reduces CXCR2 expression and blocks neutrophil chemotaxis. JBI-589 reduces primary tumor and metastases, and enhances the anti-tumor effect of checkpoint inhibitors.

Biological activity

JBI-589 (1 μM, 2 h) significantly downregulates the expression of CXCR2 on neutrophils and reduces their migration induced by CXCL1 in vitro, with no effect on the suppressive activity of Ly6G cells generated from HPCs JBI-589 (50 mg/kg, p.o., twice a day for 24 days) significantly inhibits the growth of primary tumors in LL2 and B16F10 tumor C57BL/6 mouse models

Identifiers

SMILES: CC1=C(C2=CC3=CC=CC=C3N2CC4=CC=C(F)C=C4)N=C5N1C=CC(C(N6C[C@H](N)CCC6)=O)=C5
InChIKey: DUVCPNSLXBKGOK-XMMPIXPASA-N

Specifications

MW (average): 481.5639
Formula: C₂₉H₂₈FN₅O
CAS No.: 2308504-22-3
Physical state: Solid
Color: Light yellow to yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -20°C, 1 month

Solubility

Soluble in DMSO

In vitro: DMSO : 100 mg/mL

Documents

References

[1]. Deng H, et al. A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor Progression. Cancer Res. 2022 Oct 4;82(19):3561-3572.

[2]. Gajendran C, et al. Alleviation of arthritis through prevention of neutrophil extracellular traps by an orally available inhibitor of protein arginine deiminase 4. Sci Rep. 2023 Feb 23;13(1):3189.

Same target

Search Protein Arginine Deiminase

Same research area

Search Cancer